<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>유리체강내 애플리버셉트(Aflibercept) 8 mg – CANDELA</title>
  <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.7.0/jquery.min.js"></script>
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
  <link rel="stylesheet" href="assets/css/styles2.css">
  <link rel="stylesheet" href="assets/fonts/fontawesome-all.min.css">
</head>

<body>
  <div class="row">
    <h3 style="font-size: 28px; width: 100%; color: white; font-weight: bold; background: #00617f; padding-top: 10px; padding-bottom: 10px; padding-left: 25px; margin-bottom: 10px;">유리체강내 애플리버셉트(Aflibercept) 8 mg – CANDELA</h3>
  </div>

  <div class="tab-container">
    <div class="tabs">
        <button class="tab-button" onclick="openTab('summary')">요약</button>
        <button class="tab-button" onclick="openTab('design')">Design</button>
        <button class="tab-button" onclick="openTab('results')">Results</button>
        <button class="tab-button" onclick="openTab('safety')">Safety</button>
        <button class="tab-button" onclick="openTab('references')">Reference</button>

        
        <div class="tabs-footer-1">
          <button
          type="button" 
          class="btn btn-abbrev btn-popover" 
          data-bs-container="body" 
          data-bs-html="true" 
          data-bs-position="auto"
          data-bs-trigger="manual"
          title="Abbreviations" 
          data-bs-content="
          <strong>AE</strong> adverse event<br>
          <strong>APTC</strong> Anti-Platelet Trialists' Collaboration<br>
          <strong>BCVA</strong> best-corrected visual acuity<br>
          <strong>CNV</strong> choroidal neovascularization<br>
          <strong>CRT</strong> central retinal thickness<br>
          <strong>ETDRS</strong> Early Treatment Diabetic Retinopathy Scale<br>
          <strong>IOP</strong> intraocular pressure<br>
          <strong>IRF</strong> intraretinal fluid<br>
          <strong>IVT-AFL</strong> intravitreal aflibercept<br>
          <strong>n</strong> number<br>
          <strong>nAMD</strong> neovascular age-related macular degeneration<br>
          <strong>PED</strong> pigment epithelial detachment<br>
          <strong>PRN</strong> pro re nata (as needed)<br>
          <strong>q4</strong> every 4 weeks<br>
          <strong>q12</strong> every 12 weeks<br>
          <strong>SE</strong> standard error <br>
          <strong>SRF</strong> subretinal fluid<br>
          <strong>TEAE</strong> treatment-emergent adverse event<br>">
          <i id ="fa" class="fas fa-list"></i>
          </button>Abbreviations
        </div>
        
        <div class="tabs-footer-2">
        <button
        type="button" 
        class="btn btn-ref btn-popover" 
        data-bs-container="body" 
        data-bs-html="true" 
        data-bs-position="auto"
        data-bs-trigger="manual"
        title="Reference" 
        data-bs-content="
        <ol>
          <li>
            Wykoff CC, Brown DM, Reed K, et al. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial (incl suppl). <em>JAMA Ophthalmol</em>. 2023;141(9):834-842.
            <br><a href='https://pubmed.ncbi.nlm.nih.gov/37535382/' target='_blank'>PMID: 37535382</a>
          </li>
        </ol>">
        <i id="fa" class="fas fa-scroll"></i>
        </button>
        Reference
      </div>

    </div>

    <div class="content-container">
      <div id="summary" class="tab-content">
        <h2>요약<sup>1</sup></h2>
        <ul class="bullet">
          <li>
            <a href="https://www.clinicaltrials.gov/study/NCT04126317" target="_blank">CANDELA</a> 연구는 치료 경험이 없는 신생혈관 연령 관련 황반변성(neovascular age-related macular degeneration, nAMD) 환자에서 유리체내 애플리버셉트(intravitreal aflibercept, IVT-AFL) 8 mg과 2 mg의 효능과 안전성 프로파일을 평가한 무작위배정, 다기관, 단일맹검, 제2상 연구입니다.
          </li>
          <li>
            중심 황반에 액체가 없는 눈의 비율:
             <ul>
              <li>
                제16주
                <ul>
                  <li>
                    8 mg 군에서는 50.9%(27/53), 2 mg군에서는 34.0%(18/53)
                  </li>
                  <ul>
                    <li>
                      차이: 17.0%; 95% CI -1.6 ~ 35.5; P = 0.08
                    </li>
                  </ul>
                </ul>
              </li>
              <li>
                제44주
                <ul>
                  <li>
                    8 mg 군에서는 39.6%(21/53), 2 mg군에서는 28.3%(15/53)
                  </li>
                  <ul>
                    <li>
                      차이: 11.3%; 95% CI -6.6 ~ 29.2; P = 0.22
                    </li>
                  </ul>
                </ul>
              </li>
             </ul> 
          </li>
          <li>
            기준치로부터 제44주까지 최고 교정 시력(best corrected visual acuity, BCVA) 평균 변화는 8 mg 군에서 7.9글자였고, 2 mg군에서 5.1글자였습니다.
          </li>
            <ul>
              <li>
                최소 제곱 평균 차이: 2.8; 95% CI -1.4 ~ 7.0글자; P = 0.20
              </li>
            </ul>
          <li>
            두 군 간의 안전성 프로파일에는 차이가 관찰되지 않았습니다.
          </li>
        </ul>
        </div>

      <div id="design" class="tab-content">
        <h2>Design<sup>1</sup></h2>
        <ul class="bullet">        
          <li>
            Treatment-naive patients with active subfoveal CNV secondary to nAMD and BCVA ETDRS score of 78 to 24 letters were randomized 1:1 to receive IVT-AFL 8 mg (n=53) or IVT-AFL 2 mg (n=53) for 3 monthly doses followed by q12 (Week 20 and Week 32). 
          </li>
          <li>
            Patients were permitted to receive PRN treatment at Weeks 24, 28, 36, and 40 if they met the following criteria: loss of &ge;5 letters from Week 20 due to disease progression or anatomical findings such as worsening/persistent retinal fluid, new/worsening retinal PED, or new/persistent hemorrhage.
          </li>
          <li>
            The coprimary endpoints were proportion of eyes without fluid in the center subfield at Week 16 and safety.
          </li>
        </ul>

        <div class="container-button">
          <button class="open-popup-btn" data-popup-target="#popup1">Click to see dosing regimens</button>
        </div>

        <div id="popup1" class="popup">
          <div class="popup-content">
              <span class="close-btn">&times;</span>
              <img src="assets/img/dosing-candela.png">
          </div>
        </div>
      </div>
        
      <div id="results" class="tab-content">
        <h2>Results<sup>1</sup></h2>
        
        <div class="container-button2">
          <div class="results-buttons">
            <button class="results-tab-button" onclick="showResultsSection('patients', event)">Patients</button>
            <button class="results-tab-button" onclick="showResultsSection('keyAnatomic', event)">Key Anatomic Endpoints</button>
            <button class="results-tab-button" onclick="showResultsSection('visualOutcomes', event)">Visual Outcomes</button>
        </div>
        </div>
        
        <div id="patients" class="results-section">
          <ul class="bullet">
            <li>
              Of the 106 patients enrolled, 100 patients completed Week 44 of the study (8 mg, n=51; 2 mg, n=49). 
            </li>
            <li>
              Baseline mean BCVA was 57.9±13.6 letters in the 8 mg group and 58.2±10.5 letters in the 2 mg group.
            </li>
            <li>
              Through Week 44, the mean number of injections in patients completing the study was 5.8 for IVT-AFL 8 mg and 5.9 for IVT-AFL 2 mg. 
            </li>
            <li>
              The total number of PRN injections administered was 33 in the 8 mg group and 38 in the 2 mg group.
              <ul>
                <li>
                  Of patients who completed the study, a total of 29/51 eyes (56.9%) in the 8 mg group and 24/49 eyes (49.0%) in the 2 mg group did not receive PRN/additional treatment.
                </li>
              </ul> 
            </li>
          </ul>
        </div>

        <div id="keyAnatomic" class="results-section" style="display: none;">
          <ul class="bullet">
            <li>
             At Week 16, 27/53 (50.9%) patients in the 8 mg group had no fluid in the central subfield vs 18/53 (34.0%) patients in the 2 mg group (treatment difference 17.0%; 95% CI -1.6 to 35.5; P=0.08)
            </li>
            <li>
              At Week 44, 21/53 (39.6%) patients in the 8 mg group had no fluid in the central subfield vs 15/53 (28.3%) patients in the 2 mg group (treatment difference 11.3%; 95% CI -6.6 to 29.2; P=0.22)
            </li>
          </ul>
          
          <div class="container-button">
            <button class="open-popup-btn" data-popup-target="#popup2">Click to see proportion of<br>eyes without fluid</button>
          </div>
  
          <div id="popup2" class="popup">
            <div class="popup-content">
                <span class="close-btn">&times;</span>
                <img src="assets/img/primary-outcome-candela.png">
            </div>
          </div>

          <ul class="bullet">
            <li>
              The mean (SE) change in CRT from baseline to Week 44 was -159.4 (16.4) μm for the 8 mg group and -137.2 (22.8) μm for the 2 mg group (least squares mean difference: -9.5; 95% CI -51.4 to 32.4; P=0.65)
            </li>
          </ul>

          <div class="container-button">
            <button class="open-popup-btn" data-popup-target="#popup3">Click to see<br> mean change in CRT</button>
          </div>
  
          <div id="popup3" class="popup">
            <div class="popup-content">
                <span class="close-btn">&times;</span>
                <img src="assets/img/crt-candela.png">
            </div>
          </div>
        </div>
        
        <div id="visualOutcomes" class="results-section" style="display: none;">
          <ul class="bullet">
            <li>
              Mean (SE) change in BCVA from baseline to Week 44 was 7.9 (1.5) letters in the 8 mg group vs 5.1 (1.5) letters in the 2 mg group.
              <ul>
                <li>
                  Least squares mean difference: 2.8; 95% CI -1.4 to 7.0 letters; P=0.20
                </li>
              </ul>
            </li>
          </ul>

          <div class="figure-white">
            <img src="assets/img/bcva-candela.png" 
            class="img-fluid">
        </div>

        </div>
      </div>

      <div id="safety" class="tab-content">
        <h2>Safety<sup>1</sup></h2>
        <ul class="bullet">
          <li>
            Overall, no new safety signals were identified. The overall safety of 8 mg IVT-AFL was similar to that of IVT-AFL 2 mg.
          </li>
        </ul>

        <div class="container">
          <div class="row" style="margin-left: 30px; margin-right: 30px;">
            <div class="col" style="background-color: #e5eff2; margin-bottom: 10px;">
              <p style="margin-left: 10px; margin-bottom: 5px;font-size: 22px; text-decoration: underline">
                Ocular Safety
              </p>
              <ul style="font-size: 20px;">
                <li>
                  No vascular occlusive events
                  <ul>
                    <li>
                      There was 1 case of iritis in the 8 mg group, which was mild and resolved with topical therapy.
                    </li>
                  </ul>
                </li>
                <li>
                  No IOP increases of clinical concern in either group
                </li>
              </ul>
            </div>
            <div class="col" style="background-color: #e5eff2; margin-bottom: 10px;">
              <p style="margin-left: 15px; margin-bottom: 5px; font-size: 22px; text-decoration: underline">
                Non-Ocular Safety
              </p>
              <ul style="font-size: 20px;">
                <li>
                  2 cases (one in each treatment group) of non-serious worsening hypertension
                </li>
                <li>
                  No APTC AEs
                </li>
                <li>
                  One death in the 8 mg group (occurred after study withdrawal due to glioblastoma and was not considered related to study treatment)
                </li>
              </ul>
            </div>
          </div>
        </div>

        <div class="container-button">
          <button class="open-popup-btn" data-popup-target="#popup4">Click to see key TEAEs</button>
        </div>

        <div id="popup4" class="popup">
            <div class="popup-content">
              <span class="close-btn">&times;</span>
                <img src="assets/img/safety-candela.png">
            </div>
        </div>
      </div>

      <div id="references" class="tab-content">
        <h2>Reference</h2>
        <ol>
          <li>
            Wykoff CC, Brown DM, Reed K, et al. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial (incl suppl). <em>JAMA Ophthalmol</em>. 2023;141(9):834-842.
            <br><a href="https://pubmed.ncbi.nlm.nih.gov/37535382/" target="_blank">PMID: 37535382</a>
          </li>
        </ol>
      </div>
    </div>
  </div>

  <script src="assets/js/javascript2.js"></script>
  <script>  
    $(document).ready(function() {
      // Initialize all popovers with the class 'btn-popover'
      var popoverTriggers = $('.btn-popover').popover();
    
      popoverTriggers.on('click', function() {
        // Close any open popovers first
        popoverTriggers.not(this).popover('hide');
    
        // Toggle the current popover
        var isOpen = $(this).attr('aria-describedby'); // Checks if the popover is open
    
        if (isOpen) {
          $(this).popover('hide');
        } else {
          $(this).popover('show');
        }
      });
    
      // Optional: Close popovers when clicking anywhere else on the page
      $(document).on('click', function(e) {
        if (!popoverTriggers.is(e.target) && popoverTriggers.has(e.target).length === 0 && $('.popover').has(e.target).length === 0) {
          popoverTriggers.popover('hide');
        }
      });
    });
    </script> 
  </body>

</html>